English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Colorectal cancer (CRC) is one of the most common cancers in China. Both the incidence and mortality of CRC ranked fifth in 2015, with 276,000 new cases and 191,000 deaths, respectively (1). Surgical resection, chemotherapy, and molecular targeted therapy are the major treatment options for CRC. However, 30–40% of patients who receive systematic treatment will relapse (2). The 5-year survival rate of CRC in China is around 55%, and the 5-year survival rate of patients with stage IV CRC is <10% (3). It is important that the therapeutic regime Original Article

Expression of biogenesis of ribosomes BRX1 is associated with malignant progression and prognosis in colorectal cancer